Page 42 - Compass Pathways News Today

Three stocks are rich in growth potential, but everyone is afraid of buying them.

Alexander_Volkov/Getty Images Atai Life Sciences, the largest private psychedelics company in the world, just raised $157 million. The fresh round of capital comes months after the company closed a record $125 million in November. CEO Florian Brand told Insider the money will be used to "double down" on the companys strategy. Just months after breaking the record for largest funding round in the psychedelics field, Atai Life Sciences has raised another $157 million...

International VC firm Presight Capital raises $350M second fund Presight Capital has closed its $350 million second fund only a year and a half after it announced an $80 million first fund. In fact, General Partner Christian Angermayer told me that the fund was raised in just a few weeks, and that it shot past the initial goal of $250 million. Presight is the international venture arm of Angermayer’s family office Apeiron Investment Group, which has more than $2.5 billion under management. Wh...

Article content Atai Life Sciences AG, a German startup looking into ways of using psychedelic substances to treat mental-health disorders, has been valued at about US$2 billion in a funding round ahead of its potential listing, people familiar with the matter said. Berlin-based Atai plans to hire Credit Suisse Group AG and Citigroup Inc. for a potential U.S. initial public offering that could take place as early as the second quarter, the people said, asking not to be identified because the in...

Atai Life Sciences has raised $157 million in venture capital. The Series D funding round is being touted as the psychedelics sector’s largest to date. Christian Angermayer, who founded Atai in 2018, led the effort with Thiel Capital, the venture capital firm of tech billionaire Peter Thiel. Apeiron Investment Group and Woodline Partners LP also participated. “We are excited to continue supporting atai, the only company in neuropsychiatry today that is thoughtfully pursuing platform...

Field Trip Intends to Use the Net Proceeds From the Offering for the Development of the Company’s FT-104 Novel Psychedelic Development Program, the Opening of New Field Trip Health Centers, and for Working Capital and General Corporate Purposes Field Trip Health (OTC:FTRPF) announced that, due to strong demand, it has agreed with a syndicate of underwriters led by Bloom Burton Securities, to increase the size of its previously announced $50,000,015 bought deal offering. Pursuant to the upsiz...

Thanks to Philanthropic Support From Several Donors, a Renowned Institution Will Create a New Research Center Dedicated Entirely to the Field of Psychedelic Medicine More than $10 million in donations will help establish the new NYU Langone Center for Psychedelic Medicine, where researchers will continue their work on psychedelics with a focus on psychiatry, medicine, and preclinical research. It will also create a dedicated psychedelic medicine research training program, something that Dr. Mic...

Psychedelic Stocks Poised to Resume the Upward Trend News Provided By Share This Article Fears of inflation and higher interest rates roiled the market for growth stocks, but the long-term prospects for psychedelic medicine remains bullish /EIN News/ -- ATLANTA, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Fears of inflation and higher interest rates sent the NASDAQ Composite and Russell 2000 lower the past few weeks as many investors ran for cover. Almost as if on command, the same market pundits who w...

The mental health wellness sector is poised to expand as mental health issues continue to disrupt the world. Every year, mental health disorders cost the global economy US$2.5 trillion. Companies that are helping society tackle this crisis have raised significant investment and gained widespread attention, especially in the wake of the COVID-19 pandemic. Significant investments in the mental health space In recent months, an increasing number of major investments have been made in the mental he...

3 Min Read BERLIN (Reuters) - German investor Christian Angermayer is planning to list a blank-cheque company in New York, embracing a trend that has seen a swathe of entrepreneurs tapping into investor interest in new offerings, two people close to the matter said. His Frontier Acquisition Corp., a special purpose acquisition company (SPAC), is planning to sell shares worth $200 million and will have a biotech focus, the sources said, adding that an official filing could take place in the comi...